Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 22, 2020.
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
In an effort to help continue to provide the most up to date resources and educational opportunities for health care providers, NeurologyLive has partnered with the Consortium of Multiple Sclerosis Centers (CMSC) to convert many of the planned educational sessions from the in-person meeting to a virtual format, which will be held May 26-29, 2020.
The staff neurologist, Vice Chair of Operations, and Quality Improvement Officer at Cleveland Clinic Neurological Institute discussed the institute’s transition to telemedicine and how it has been utilized.
Compared to those with normal fasting glucose levels, those with Type 2 diabetes had poorer cognitive performance at 3 and 6 months after suffering a stroke, based on data from the STROKOG consortium.
Key opinion leader Fernando L. Pagan, MD, reviews evolving poly-pharmacological treatment approaches and incorporating on-demand therapies for Parkinson disease off episodes.
The new data further cemented the therapy’s consistent safety profile from previous studies as well as demonstrated newfound durability in patients with later-onset spinal muscular atrophy.